| Literature DB >> 35267536 |
Xhyljeta Luta1, Sara Colomer-Lahiguera1, Rodrigo Jose Martins Cardoso2, Frank Hof3, Manon Savoie1, Cosette Schuler4, Justine Wicht1, Nadia Fucina5, Patricia Debarge4, Françoise Ninane2, Jean Bourhis2, Manuela Eicher1,4.
Abstract
BACKGROUND: Head and neck cancer (HNC) patients experience distressing symptoms that can significantly impact their health-related quality of life (HRQoL). We analyzed the implementation of a nurse-led consultation (NLC) and explored potential associations with symptom burden in HNC patients.Entities:
Keywords: cancer rehabilitation; head and neck cancer-related symptoms; patient-reported outcomes; radiotherapy
Year: 2022 PMID: 35267536 PMCID: PMC8909718 DOI: 10.3390/cancers14051227
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Figure 1Participant enrolment process.
Demographic and clinical characteristics of patients by treatment group.
| Characteristics | Routine Care | NLC | |
|---|---|---|---|
| Age (mean, SD) | 63.7 (11.0) | 63.5 (12.0) | 0.62 |
| Gender | | | 0.93 |
| Marital status | 0.39 | ||
| Married | 39 (54.2) | 29 (46.7) | |
| Not married | 33 (45.8) | 33 (53.2) | |
| Alcohol | 0.50 | ||
| Yes | 33 (45.8) | 32 (51.6) | |
| No | 39 (54.2) | 30 (48.4) | |
| Smoking | |||
| Yes | 26 (36.1) | 14 (22.6) | 0.08 |
| No | 46 (63.9) | 48 (77.4) | |
| Weight before radiotherapy (kg), mean (SD) | 72.6 (13.9) | 71.7 (14.9) | 0.29 |
| Pre-existing conditions | <0.0001 | ||
| Yes | 64 (88.9) | 39 (62.9) | |
| No | 8 (11.1) | 23 (37.1) | |
| Pre-existing oncological conditions | <0.000 | ||
| Yes | 21 (29.2) | 20 (32.3) | |
| No | 51 (70.8) | 42 (67.7) | |
| Cancer recurrence | 0.04 | ||
| Yes | 7 (9.7) | 14 (22.6) | |
| No | 65 (90.3) | 48 (77.4) | |
| Cancer location | <0.000 | ||
| Oropharynx | 27 (37.5) | 33 (53.2) | |
| Oral cavity | 15 (20.8) | 1 (1.6) | |
| Nasopharynx | 2 (2.8) | 4 (6.4) | |
| Larynx | 11 (15.3) | 3 (4.8) | |
| Hypopharynx | 11 (15.3) | 3 (4.8) | |
| Salivary glands | 4 (5.6) | 8 (12.9) | |
| Nasal cavity | 0 (0.0) | 7 (11.3) | |
| Thyroid | 2 (2.8) | 1 (1.6) | |
| Stage | 0.14 | ||
| I | 3 (4.2) | 4 (6.4) | |
| II | 9 (12.5) | 9 (14.5) | |
| III | 17 (23.6) | 13 (20.9 | |
| IV | 42 (58.3) | 29 (46.7) | |
| Unknown | 1 (1.4) | 7 (11.3) | |
| Treatment type | 0.38 | ||
| Radiotherapy only | 6 (8.3) | 8 (12.9) | |
| Radiotherapy and other | 66 (91.6) | 54 (87.1) | |
| Radiotherapy sessions (mean, SD) | 32.2 (1.4) | 32.5 (1.3) | 0.29 |
| Radiation dose (Gy, mean SD) | 63.6 (6.8) | 64.4 (6.7) | 0.68 |
| Radiotherapy interruption | 0.68 | ||
| Yes | 12 (16.7) | 12 (19.3) | |
| No | 60 (83.3) | 50 (80.6) | |
| Tube placement during radiotherapy | 0.02 | ||
| Yes | 29 (59.7) | 14 (77.4) | |
| No | 43 (40.3) | 48 (22.6) | |
| Hospitalization during radiotherapy | 0.37 | ||
| Yes | 12 (16.7) | 7 (11.3) | |
| No | 60 (83.3) | 55 (88.7) | |
| Total | 72 (100.0) | 62 (100.0) |
NLC: nurse-led consultation.
Number of nursing interventions provided, according to the intervention domain during the consultations at three different times during radiotherapy treatment.
| Consultations | T0 | T1 | T2 | |
|---|---|---|---|---|
| Variables | Interventions | |||
| Nutrition | Screening | 63 (100) | 62 (98.4) | 40 (97.6) |
| Education | 37 (58.7) | 11 (17.5) | 12 (29.3) | |
| Coordination | 19 (30.2) | 13 (20.6) | 9 (22.0) | |
| Smoking | Screening | 61 (96.8) | 59 (93.7) | 34 (83.0) |
| Education | 10 (15.9) | 6 (9.5) | 0 | |
| Coordination | 4 (6.4) | 1 (1.6) | 0 | |
| Pain | Screening | 44 (69.8) | 41 (65.1) | 26 (63.4) |
| Education | 3 (4.8) | 16 (25.4) | 11 (26.8) | |
| Coordination | 4 (6.3) | 0 | 1 (2.4) | |
| Oral cavity status | Screening | 60 (95.2) | 59 (93.7) | NA |
| Education | 60 (95.2) | 46 (73.0) | NA | |
| Coordination | 0 | 0 | NA | |
| Swallowing/chewing capacity | Screening | 57 (90.5) | 51(81.0) | NA |
| Education | 0 | 0 | NA | |
| Coordination | 6 (9.5) | 3 (4.8) | NA |
* N = 41 patients who met the criteria for the third consultation. T0 = nursing consultation (new case) between the location of scan and the first week of radiotherapy. T1 = follow-up nurse consultation between the third and the fourth weeks of radiotherapy. T2 = nursing consultation (end of treatment) between the fifth and sixth weeks of radiotherapy. NA: not applicable (not reported).
Results of the data collection during nurse-led consultations.
| Variables | T0 | T1 | T2 | ||||
|---|---|---|---|---|---|---|---|
| MED (IQR) | MED (IQR) | MED (IQR) | |||||
| Nutrition | |||||||
| Weight | Screening | 62 (100) | 62 (98.4) | 40 (97.6) | |||
| Kg | 70 (19.9) | 67.2 (17.4) | 67.4 (14.8) | ||||
| Kondrup a | Screening | 57 (90.5) | 2.0 (1.0) | NA | NA | NA | NA |
| Kondrup ≥ 3 | 13 (20.6) | 3.0 (1.0) | |||||
| Smoking | Screening | 61 (96.8) | 59 (93.7) | 34 (83.0) | |||
| Status | Non-smoker | 46 (73.0) | 48 (76.2) | 32 (78.1) | |||
| Smoker | 15 (23.8) | 11 (17.5) | 2 (4.9) | ||||
| Attitude b | Ambivalent | 5 (33.0) | 3 (27.0) | 1 (50.0) | |||
| Motivated | 7 (47.0) | 4 (36.0) | 1 (50.0) | ||||
| Consumption | Screening | 11(73.0) | 10 (91.0) | 2 (100) | |||
| 20 (21) | 10.0 (10) | 25 (10) | |||||
| Pain | Screening | 44 (69.8) | 41 (65.1) | 26 (63.4) | |||
| Score EVA d | 0 (3.0) | 2.0 (4.0) | 3.0 (5.0) | ||||
| Oral status | Screening | 60 (95.2) | 59 (93.7) | NA | NA | ||
| Score OAG e | 1.5 (3.0) | 3.0 (3.0) | |||||
| Swallowing/chewing capacity (dysphagia) | Screening | 57 (90.5) | 51 (81.0) | NA | NA | ||
| Absence | 45 (71.4) | 38 (60.3) | |||||
| Presence | 5 (7.9) | 9 (14.3) | |||||
| Dysphagia associated with other symptoms f | 7 (11.1) | 4 (6.4) | |||||
T0 = between third and fourth weeks of radiotherapy, T2 = between fifth and sixth weeks of radiotherapy, MED = median, IQR = interquartile range, a: Kondrup nutrition risk score values possible between 0 and 5; b: attitude towards smoking cessation (refers to smokers only); c: number of cigarettes per day (refers to smokers only); d: VAS with possible values between 0 and 10; e: Oral Assessment Guide (OAG) with possible values ranging between 1 and 16; and f: drooling, coughing, change of voice after meals, and accumulation of food in the mouth.
Figure 2Distribution of data in the routine care and consultation group at three different times across the main MDASI-HN dimensions: core symptoms (A); head and neck symptoms (B); and interference symptoms (C).
M.D. Anderson HN mean scores and baseline-adjusted differences for routine care group (RC) and nurse-led intervention group (NLC).
| MDASI-HN Dimensions | T1 (3rd–4th Week) | T2 (5th–6th Week) | ||||||
|---|---|---|---|---|---|---|---|---|
| Mean (RC) | Mean (NLC) | Mean Difference (95% CI) | Mean (RC) | Mean (NLC) | Mean Difference (95% CI) | |||
| Core symptoms | ||||||||
| Pain | 3.4 | 3.0 | 0.40 (−1.35–0.53) | 0.39 | 4.5 | 4.0 | −0.49 (−1.45–0.46) | 0.31 |
| Fatigue | 3.8 | 3.8 | −0.01 (−0.84–0.82) | 0.98 | 4.9 | 4.6 | −0.30 (−1.13–0.52) | 0.47 |
| Nausea | 1.4 | 1.5 | 0.11 (0.66–0.88) | 0.77 | 2.0 | 2.0 | −0.02 (−0.94–0.89) | 0.96 |
| Disturbed sleep | 2.3 | 2.7 | 0.37 (−0.55–1.29) | 0.43 | 2.5 | 2.8 | 0.24 (−0.63–1.12) | 0.58 |
| Being distressed (worried) | 2.7 | 2.9 | 0.18 (−0.72–1.09) | 0.69 | 2.8 | 2.9 | 0.13 (−0.78–1.04) | 0.77 |
| Shortness of breath | 1.9 | 1.9 | 0.06 (−0.75–0.88) | 0.87 | 2.0 | 1.9 | −0.09 (−0.90–0.70) | 0.81 |
| Difficulty remembering | 2.7 | 2.9 | 0.18 (−0.72–1.09) | 0.69 | 2.8 | 2.9 | 0.13 (−0.78–1.04) | 0.77 |
| Lack of appetite | 3.1 | 2.7 | −0.36 (−1.37–0.64) | 0.47 | 4.3 | 3.7 | −0.60 (−1.64–0.43) | 0.25 |
| Drowsiness | 2.3 | 2.2 | −0.07 (−0.84–0.70) | 0.85 | 3.2 | 2.9 | −0.24 (−1.17–0.68) | 0.60 |
| Dry mouth | 4.7 | 4.3 | 0.23 (−1.27–0.81) | 0.45 | 5.1 | 4.9 | −0.23 (−1.27–0.81) | 0.66 |
| Sadness | 2.5 | 2.9 | 0.41 (−0.58–1.39) | 0.41 | 2.7 | 2.9 | 0.18 (−0.84–1.20) | 0.72 |
| Vomiting | 0.6 | 0.7 | 0.02 (−0.55–0.61) | 0.92 | 1.5 | 1.0 | −0.43 (−1.25–0.38) | 0.29 |
| Numbness/tingling | 1.1 | 1.5 | 0.42 (−0.24–1.10) | 0.21 | 1.7 | 1.8 | 0.12 (−0.75–1.00) | 0.77 |
| Head and neck symptoms | ||||||||
| Mucus | 3.5 | 3.7 | 0.21 (−0.78–1.21) | 0.67 | 4.4 | 4.6 | 0.27 (−0.68–1.22) | 0.57 |
| Difficulty with swallowing/chewing | 4.4 | 3.8 | −0.57 (−1.61–0.46) | 0.28 | 5.3 | 4.6 | −0.63 (−1.69–0.42) | 0.24 |
| Coughing/choking | 1.7 | 1.6 | 0.32 (−1.30–0.65) | 0.86 | 1.6 | 1.7 | −0.32 (−1.30–0.65) | 0.51 |
| Difficulty with voice/speech | 3.1 | 3.2 | 0.07 (−0.86–1.02) | 0.87 | 3.9 | 3.9 | −0.02 (−1.05–1.01) | 0.96 |
| Burning/rash | 2.5 | 2.3 | 0.52 (−1.56–0.50 | 0.31 | 4.4 | 3.9 | −0.52 (−1.56–0.50) | 0.31 |
| Constipation | 1.8 | 2.2 | 0.37 (−0.58–1.33) | 0.63 | 2.7 | 2.4 | −0.24 (−1.25–0.77) | 0.63 |
| Problem with tasting food | 4.0 | 3.7 | −0.37 (−1.55–0.79) | 0.53 | 5.8 | 5.1 | −0.64 (−1.83–0.54) | 0.28 |
| Mouth/throat sores | 3.4 | 3.5 | 0.11 (−0.97–1.20) | 0.83 | 4.4 | 4.3 | −0.03 (−1.13–1.06) | 0.94 |
| Problem with teeth or gums | 2.3 | 3.0 | 0.69 (−0.27–1.67) | 0.16 | 2.8 | 3.0 | 0.20 (−0.80–1.21) | 0.69 |
| Interference symptoms | ||||||||
| General activity | 3.4 | 3.4 | 0.07 (−0.88–1.03) | 0.87 | 4.0 | 4.1 | 0.09 (−0.88–1.07) | 0.84 |
| Mood | 2.9 | 3.3 | 0.36 (−0.61–1.33) | 0.46 | 3.5 | 3.3 | 0.36 (−0.61–1.33) | 0.46 |
| Work | 3.8 | 3.4 | −0.46 (−1.58–0.64) | 0.41 | 3.7 | 4.0 | 0.35 (−0.72–1.42) | 0.52 |
| Relationships with others | 2.4 | 2.3 | −0.12 (−0.98–0.73) | 0.77 | 2.8 | 2.7 | −0.11 (−0.98–0.75) | 0.79 |
| Walking | 2.2 | 2.1 | −0.17 (−1.09–0.75) | 0.71 | 2.7 | 1.7 | −0.96 (−1.85–0.08) | 0.03 |
| Joy of living | 2.6 | 3.5 | 0.93 (−0.08–1.95) | 0.07 | 2.6 | 3.3 | 0.66 (−0.35–1.67) | 0.20 |
Figure 3Change in symptoms in the routine care (A) and consultation group (B) at three different times during radiotherapy treatement.